PERIOPERATIVE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ROUTINE ONCOSURGERY

The article is devoted the problem of prevention of perioperative venous thromboembolic complications (VTEC) in cancer patients. The study identifies the causes of thrombosis in this category of patients and describes in details the major and minor risk factors for the development of VTEC. The results of studies on the influence of the morphological characteristics of the tumor, the stage and location of tumor on the risk of development of  VTEC are performed. It is noted that along with the likelihood of thrombosis, cancer patients at the stages of surgical treatment there is an alternative risk factor – bleeding. The frequency of hemorrhagic complications and their risk increases in the presence of disintegration of the tumor, its proximity to the main vessels, extent of surgical aggression, as well as due to the introduction of anticoagulants. The approaches to the selection of the optimal method is specific or nonspecific prevention of VTEC depending on the nature and volume of the intervention, estimated blood loss and patients’ rehabilitation time are described. We show the advantages of  low  molecular weight heparins compared with unfractionated heparin for the prevention of VTEC in Oncology. The article presents long-term experience of employees of one of the leading cancer institutions in Russia – P. Hertsen MORI, whose team took an active part in the development of Russian clinical guidelines for the prevention and treatment of VTEC in Oncology.

1. Donnellan E., Kevane B., Bird B. R., Ainle F. N. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol. 2014; 21 (3): 134–143. DOI: 10.3747/co.21.1864

2. Prandoni P., Lensing A. W., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100 (10): 3484–3488. DOI: 10.1182/blood-2002–01–0108

3. Chissov V. I., Osipova N. A., Ermolayev P. M., Kotin M. Yu., Eldarkhanov D. R., Khovanskaya T. P. Thromboembolic and hemorrhagic complications in cancer surgery. Rossiiskii onkologicheskii zhurnal (Russian Journal of Oncology). 2011; 1: 26–29. (In Russian).

4. Lardas M., Stewart F., Scrimgeour D., Hofmann F., Marconi L., Dabestani S., et al. Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. Eur Urol. 2016; 70 (2): 265–280. DOI: 10.1016/j.eururo.2015.11.034

5. Falanga A., Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2012; 32 (2): 115–125. DOI: 10.5482/ha-1170

6. Timp J. F., Braekkan S. K., Versteeg H. H., Cannegieter S. C. Epidemiology of cancer-associated venous thrombosis. Blood. 2013; 122 (10): 1712–1723. DOI: 10.1182/blood-2013–04–460121

7. Falanga A., Marchetti M., Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res. 2015; 135 Suppl 1: S8-S11. DOI: 10.1016/s0049–3848(15)50432–5

8. Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 Feb 9; 293 (6): 715–722. DOI: 10.1001/jama.293.6.715

9. Horsted F., West J., Grainge M. J. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012; 9 (7): e1001275. DOI: 10.1371/journal.pmed.1001275

10. Rossiiskie klinicheskie rekomendatsii po profilaktike i lecheniyu venoznykh tromboembolicheskikh oslozhnenii u onkologicheskikh bol’nykh [The Russian clinical practice guidelines for the prevention and treatment of venous thromboembolism in cancer patients]. Мoscow: “Planida” Publ., 2012. 34 p. (In Russian).

11. Gavriel H., Thompson E., Kleid S., Chan S., Sizeland A. Safety of thromboprophylaxis after oncologic head and neck surgery. Study of 1018 patients. Head Neck. 2013; 35 (10): 1410–1414. DOI: 10.1002/hed.23158

12. Clayburgh D. R., Stott W., Cordiero T., Park R., Detwiller K., Buniel M., et al. Prospective study of venous thromboembolism in patients with head and neck cancer after surgery. JAMA Otolaryngol Head Neck Surg. 2013; 139 (11): 1143–1150. DOI: 10.1001/jamaoto.2013.4911

13. Francis C. W. Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol. 2009; 27 (29): 4874–4880. DOI: 10.1200/jco.2009.22.3644

14. Khorana A. A., Connolly G. C. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009; 27 (29): 4839–4847. DOI: 10.1200/jco.2009.22.3271

15. Ay C., Pabinger I. Tests predictive of thrombosis in cancer. Thromb Res. 2010; Research’n Practical Medicine Journal. 2016, V. 3, №4, с. 61-69 125 Suppl 2: S12–5. DOI: 10.1016/s0049–3848 (10)70005–0

16. Lyman G. H., Khorana A. A., Kuderer N. M., Lee A. Y., Arcelus J. I., Balaban E.P, et al. Venous thromboembolism prophylaxis and treatment in patient with cancer: American Society of Clinical Oncology practice guideline update. J Clin Oncol. 2013 Jun 10; 31 (17): 2189–2204. DOI: 10.1200/jco.2013.49.1118

17. Bauersachs R. M. LMWH in cancer patients with renal impairment – better than warfarin? Thromb Res. 2016 Apr; 140 Suppl 1: S160–4. DOI: 10.1016/s0049–3848(16)30116–5

18. Schmid Р., Brodmann D., Fischer A. G., Wuillemin W. A. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009; 7 (4): 552–558. DOI: 10.1111/j.1538–7836.2009.03292.x

19. Atiq F., van den Bemt P. M., Leebeek F. W., van Gelder T., Versmissen J. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency. Eur J Clin Pharmacol. 2015; 71 (8): 921–929. DOI: 10.1007/s00228–015–1880–5